Experimental dyslipidemia management through a genetic circuit enhances cholesterol homeostasis, indicating potential for tailored therapies.
Hypercholesterolemia is a complex metabolic disorder resulting from dysregulated lipid metabolism and is a significant risk factor for atherosclerosis, coronary artery disease, and myocardial infarction. To address the challenge of dyslipidemia, we present the cholesterol homeostasis and regulation module (CHARM), a designer genetic circuit engineered to sense elevated cholesterol levels in real time and strengthen the innate cholesterol homeostasis machinery. The circuit incorporates a custom fusion protein consisting of the Krüppel-associated box (KRAB) domain and a modified sterol regulatory element (SRE)-binding protein 1a (SREBP1a) as a sensor platform, along with a synthetic expression module containing SRE operator sites downstream of a constitutive promoter that enables the production of a therapeutic protein to reduce low-density lipoprotein cholesterol (LDL-C) levels in a closed-loop fashion. Implantation of microencapsulated CHARM-transgenic human cells in hypercholesterolemic mice rapidly restored and subsequently stably maintained cholesterol homeostasis.
No takes yet. Share an insight, caveat, or question.
Unal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: